Public Release: 

Treating myasthenia gravis with autologous hematopoietic stem cell transplants

The JAMA Network Journals

A report on seven cases of severe myasthenia gravis (an autoimmune disease characterized by severe muscle weakness) suggests that autologous hematopoietic stem cell transplantation (when a patient's own stem cells are used) may result in long-term remission that is symptom and treatment free, according to an article published online by JAMA Neurology.

The study by Harold Atkins, M.D., F.R.C.P.C., of the University of Ottawa and the Ottawa Hospital, Canada, and coauthors reports outcomes at the Ottawa Hospital from 2001 through 2014.

All of the patients who were treated had persistent severe or life-threatening symptoms related to myasthenia gravis (MG), although they had used intensive immunosuppressive therapies.

"The ability to control autoimmunity by autologous HSCT [hematopoietic stem cell transplantation] has been demonstrated in other treatment-refractory autoimmune conditions, including neurologic diseases. ... The role of autologous HSCT for MG warrants further exploration with prospective testing," the authors conclude.

To read the full study and a related editorial by Daniel B. Drachman, M.D., of the Johns Hopkins School of Medicine, Baltimore, please visit the For The Media website.


(JAMA Neurol. Published online April 4, 2016. doi:10.1001/jamaneurol.2016.0113. Available pre-embargo to the media at

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Media Advisory: To contact corresponding author Harold Atkins, M.D., F.R.C.P., call Jennifer Ganton at 613-798-5555 ext. 73325 or email

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.